What types of Candida infections should be included when evaluating breakthrough infections during posaconazole prophylaxis?
Antimicrob Agents Chemother
.
2013 Jun;57(6):2905.
doi: 10.1128/AAC.00189-13.
Authors
Ola Blennow
,
Mats Kalin
PMID:
23674753
PMCID:
PMC3716158
DOI:
10.1128/AAC.00189-13
No abstract available
Publication types
Letter
Comment
MeSH terms
Antifungal Agents / pharmacokinetics*
Drug Monitoring*
Female
Fungi / drug effects*
Humans
Male
Mycoses / blood*
Mycoses / prevention & control*
Triazoles / pharmacokinetics*
Substances
Antifungal Agents
Triazoles